Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB (change energy unit to kcal/mol)

Found 8 hits in this display   

TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  56nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  56nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  89nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  89nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  184nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  184nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  1.02E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161913(US10017516, Compound 45 | US9682983, 45)
Affinity DataIC50:  1.02E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent